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Key Points
• Clonal PCs in AL have similar
phenotypic and CNA profiles
as those in MM, but their
transcriptome is similar to that
of normal PCs.
• First-ever WES in AL
amyloidosis reveals potential
lack of a unifying mutation.
Immunoglobulin light-chain amyloidosis (AL) and multiple myeloma (MM) are 2 distinct
monoclonal gammopathies that involve the same cellular compartment: clonal plasma
cells (PCs). Despite the fact that knowledge about MM PC biology has significantly
increased in the last decade, the samedoes not apply for AL. Here, we used an integrative
phenotypic, molecular, and genomic approach to study clonal PCs from 24 newly
diagnosed patients with AL. Through principal-component-analysis, we demonstrated
highlyoverlappingphenotypic profilesbetweenALandbothmonoclonal gammopathyof
undetermined significance and MM PCs. However, in contrast to MM, highly purified
fluorescence-activated cell–sorted clonal PCs from AL (n 5 9) showed almost normal
transcriptome, with only 38 deregulated genes vs normal PCs; these included a few
tumor-suppressor (CDH1, RCAN) and proapoptotic (GLIPR1, FAS) genes. Notwithstand-
ing, clonal PCs in AL (n5 11) were genomically unstable, with amedian of 9 copy number
alterations (CNAs) per case, many of such CNAs being similar to those found in MM.Whole-exome sequencing (WES) performed in 5
AL patients revealed a median of 15 nonrecurrent mutations per case. Altogether, our results show that in the absence of a unifying
mutationbyWES, clonal PCs inALdisplayphenotypic andCNAprofiles similar toMM,but their transcriptome is remarkably similar to
that of normal PCs. (Blood. 2016;127(24):3035-3039)
Introduction
Light-chain amyloidosis (AL) and multiple myeloma (MM) are 2
distinct monoclonal gammopathies that involve the same cellular
compartment: clonal plasma cells (PCs). Despite the fact that
knowledge about the biology of MM PCs has greatly increased in
recent years,1 the same does not apply to AL. Thus, the cytogenetic
profile of patients with AL has only been reported in a few studies2-7
that investigated a limited number of alterations (eg, IGH translocations
or 13q and 17p deletion). Apparently, t(11;14) is the most frequent
cytogenetic alteration in AL and confers a poor outcome,4,8 whereas
MM-related high-risk cytogenetic abnormalities (ie, [t(4;14), t(14;16)
and/or del(17p)]) are prognosticallyneutral inAL.8Conversely, nodata
have been reported on copy number alterations (CNAs) and potential
recurrent mutations present in clonal PCs from AL patients.9 Of note,
the only study in which the gene expression profile (GEP) of (total)
bone marrow (BM) PCs was investigated showed that deregulated
genes in AL have intermediate expression between MM and normal
PCs,10 although this observation may result from the systematic
coexistence of clonal and normal PCs in the BM of patients with AL.11
In fact, the low incidence of AL and its typically low tumor burden,
oftenmaskedby apolyclonal PCbackground,11most probably account
for the limited information onAL tumor cell biology, particularlywhen
compared with MM. Accordingly, in this study, we characterized the
phenotypic, transcriptomic, and genetic profile of highly-purified clonal
PCs from patients with newly diagnosed AL.
Methods
Overall, 24 patients with confirmed diagnosis of AL based on the presence of
amyloid-related systemic syndrome, positive amyloid tissue stainingwithCongo
red, and evidence of PC clonality were studied. Patients’ demographics and
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Figure 1. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in AL. (A) Immunophenotypic protein expression profiles of clonal plasma cells from
patients with AL (red) and MGUS plus MM (blue). These latter patients were initially screened for bone marrow clonality using the same immunophenotypic approach because
of suspected AL, but were finally diagnosed as having MGUS (n5 3) and MM (n5 3). In the principal component analysis (PCA) graphic view, every patient is represented by
a single dot, and disease reference groups by 1 (dashed lines) and 2 (solid lines) standard deviation curves. (B) Unsupervised PCA shows differences in gene expression
profiling between clonal PCs from patients with AL (red) and normal PCs from healthy donors (green). (C) Overview of CNAs and copy number neutral loss of heterozygosity
(CNN-LOH) detected in clonal PCs from patients with newly diagnosed AL. Samples are distributed in the y-axis and chromosome location in the x-axis. Red shading indicates
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clinical characteristicsaredescribed in supplementalTable1, availableon theBlood
Web site. Samples were collected after informed consent was given, in accor-
dance with the local ethics committee guidelines and the Declaration of Helsinki.
Approximately 200 mL of EDTA-anticoagulated BM aspirate of sample
aliquots was immunophenotyped using 2 different 8-color combinations of
monoclonal antibodies, and a direct immunofluorescence stain-and-then-lyse
technique (PacB/PO/FITC/PE/ PerCP-Cy5.5/ PE-Cy7/APC/APC-H7): CD38/
CD45/b2M/CD56/CD138/CD19/cyKappa/cyLambda andCD38/CD45/CD27/
CD28/CD138/CD19/CD117/CD81. Data acquisition was performed in a FACS
Canto II flow cytometer (Becton Dickinson Biosciences [BD], San Jose, CA)
using the FACSDiva 6.1 software (BD). Generation of immunophenotypic
protein expression profiles (iPEP) based on the 12 different markers evaluated at
the single-cell level was performed as described elsewhere12 using the Infinicyt
software (Cytognos SL, Salamanca, Spain).
GEPwas performed in 9 of 24 AL cases with adequate RNA extracted from
fluorescence-activated cell sorted (FACS)-purified clonal PCs according to
patient-specific aberrant phenotypes ($95% purity), and compared with that of
normal PCs from 5 healthy individuals (FACS Aria IIb, BD). RNA was
retrotranscribed into cDNA and hybridized to the Human Gene 1.0 ST Array
(Affymetrix, Santa Clara, CA); normalization of the measured data was done
using the expression console (Affymetrix) and the RMA algorithm, which
includes background correction, normalization, and calculation of expression
(log2) values.12 Differentially expressed genes between classes were identified
using the Significant Analysis of Microarrays algorithm (http://www.statweb.
standford.edu/;tibs/SAM) and the lowest q-value (,1025).12
Genome-wide detection of CNAs and copy number–neutral (CNN) loss-of-
heterozygosity (LOH) were investigated using the Cytoscan 750K platform
(Affymetrix) in 11 of 24 cases, with adequateDNA extracted fromFACS-sorted
clonal PCs. Given that matched normal DNA was only available in a subset
of cases (n57/11), an unpaired analysiswas performedusing 240Hapmapfiles.
In those cases with paired normal DNA (peripheral blood T lymphocytes), the
latter was also used to eliminate patient-specific CNAs. The AGCC and ChAS
software programs (Affymetrix) were used for data analysis, as described
elsewhere.12,13 Full microarray data are available at the Gene Expression
Omnibus (www.ncbi.nlm.nih.gov/geo/; accession number GSE73042). Fluo-
rescence in-situ hybridization (FISH) investigating IGH translocations and
del(17p13) was also performed; del(13q14) was tested in selected cases.
Whole-exome sequencing (WES) was performed in FACS-sorted clonal
PCs and paired T lymphocytes from 5 of 24 patients with AL. Exonic sequences
were enriched using the Ion Ampliseq Exome kit (Life Technologies, Carlsbad,
CA), sequenced with a 1503 depth coverage using semiconductor technology
(IonProton,Carlsbad,CA), and analyzedwith the IonReporter andTorrent Suite
Software (Life Technologies). Single-nucleotide variants (SNVs) were consid-
ered to be positive when called by $10% variant reads. Full WES data are
available at the Sequence Read Archive under the study accession number
SRP070988 (http://www.ncbi.nlm.nih.gov/bioproject/313508).
Results and discussion
Clonal PCswere detectable in all 24 (100%) patientswith AL (median,
0.81%; range, 0.01%-30%). The median distribution between clonal/
normal PCs within the BM PC compartment was of 85%/15%, and
only in 8 of 24 (33%) cases, the majority ($95%) of PCs were
Figure 1 (continued) the presence of copy number gains, and blue indicates copy number losses. CNAs were reported when the 3 following criteria were met: $25
consecutive imbalanced markers per segment, $100 Kb minimum genomic size, and ,50% overlap with paired control DNA and/or genomic variants of Toronto DB (DGV).
Those cytogenetics alterations detected by FISH in each individual patient are detailed at the beginning of the corresponding row. CNN-LOH are represented by violet bars.
Only CNN-LOH .5 Mb, with $25 consecutive imbalanced markers per segment, and ,50% overlap with patient-paired CNAs were considered.
Table 1. CNAs and mutations detected in clonal PCs from patients with newly-diagnosed AL amyloidosis
Most frequent alteration 2nd most frequent alteration 3rd most frequent alteration Less frequent alterations
Chromosomal imbalances
Gains 19* 119* 15* 13, 16, 17, 111
Losses 2X 216 — 212, 214
Chromosomal arms
Gains 115q 11q — 18q, 19p, 111q
Losses 2Yp 213q 222q 21p, 26q, 12q, 216q
Mutations† XKR8‡ AHNAK, ALKBH4, AP3B2, ASCC3, ASIC4,
BIRC6, BSN, BTBD17, C14orf39, C22orf39,
C4orf3, CACNA1I, CATSPERD, CCDC17,
CCDC39, CELSR1, CPXCR1, CSF3R,
CTNNAL1, CTNND2, DCAF12L2, DIS3,
DNAH5, DNAH9, DSEL, EML6, ENO4,
FAM208A, FBXL21, FBXO15, FKBP3, FYCO1,
GEMIN2, GFRAL, HECW1, HIST1H3D,
HIST1H3H, HPN, IKZF1, ITSN1, KANSL1L,
KCNT1, KRAS, KRT28, LAMA3, LMX1A, LYG1,
MIA2, PTCD2, MYO18B, NAALAD2, NBEAL1,
NBR1, NFIB, OCA2, ORC4, PCLO, PDE8B,
PKD1, PLCB4, PRKD2, PRPF4B, PSCA,
PVRL3, QPCT, RAD51D, RAPGEF4, RBP3,
RETN, RGS7BP, RPL19, SALL2, SERPINA5,
SFMBT2, SI, SLX4, SPATA31D1, SPOCK1,
SPTAN1, STPG2, SWSAP1, TMEM200B,
TRADD, TTLL4, TTN, TTR, TXNRD3, USP54,
XKR8,, YTHDF2, ZFYVE1, ZNF519, ZNF729
Interstitial CNAs are detailed in supplemental Table 1.
*All 3 chromosomal gains were detected in 3 of 11 patients with AL.
†None of each SNV was simultaneously found in $2 patients.
‡Two different SNVs found in the same gene (c.445G.A and c.86C.T).
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phenotypically clonal. Aberrant PCs were identified based on down-
regulation ofCD19 (100%of cases), CD27 (67%),CD38 (42%),CD45
(53%), and CD81 (48%), and overexpression of CD117 (29%), CD28
(50%), and CD56 (61%). b2M was strongly expressed on all clonal
PCs, similar to normal PCs. Overall, the iPEP of clonal PCs in AL
overlapped with that of monoclonal gammopathy of undetermined
significance (MGUS)/MM (Figure 1A), and, similarly to the former,
transitioning from 4-color to 8-color multiparameter flow cytometry
(MFC) based on the EuroFlow approach improved the detection rate of
PC clonality in AL from 97%11 to 100% of patients. Hence, despite
lower BM PC percentages compared with conventional morphology
(partly explained because samples evaluated by the latter contain cells
associatedwith lipid-enriched spicules,whereasMFC is performed on
the BM fluid, which is depleted in the lipid-adhesive PC),2,4,8,11 MFC
represents a highly sensitive tool to demonstrate clonality in AL.
After identification and sensitive FACS-purification of clonal PCs,
we performed GEP to identify uniquely deregulated genes in AL vs
normal PCs. Even though multidimensional scaling analysis showed
differences betweenboth groupsof PCs (Figure 1B), therewere only38
genes significantly deregulated (3 upregulated and 35 downregulated)
in AL PCs (excluding 22 immunoglobulin coding genes, which are
physiologically upregulated in normal PCs and mainly reflect differ-
ences between clonal vs polyclonal PCs; supplemental Excel File 1).
Interestingly, the CDH1 and RCAN tumor-suppressor genes and
the GLIPR1 and FAS proapoptotic genes14-18 were all significantly
downregulated in AL; in contrast, IFITM1, which has been asso-
ciated with more aggressive solid tumors,19 was overexpressed in
clonal PCs. It is worth noting that CD19 and CD81 mRNAs were
significantly decreased in AL, confirming the correlation between
the iPEP and the GEP of clonal vs normal PCs. Overall, these results
indicate that, although clonal PCs in AL and MM share similarly
altered iPEP, clonal PCs in AL show a much less altered GEP than
MM, where ;400 genes have been reported to be deregulated vs
normal PCs.20
The lack of significant transcriptomic deregulation in clonal PCs
fromAL could be related to a lower genetic instability; in fact, Bochtler
et al21 have previously reported that hyperdiploid karyotypes are
significantly less frequent in AL than in MGUS or MM. Here, by
performing high-throughput genetic profiling of purified clonal PCs
(Table 1; supplemental Table 2), CNAs were detected in all cases
tested with a median number of 9 CNAs per patient (range, 1-23)
(Figure 1C), similar to what has been described for MM (median of
12CNAs/patient)13; furthermore, the pattern ofCNAobserved inAL
was also similar to that observed inMM.13 Interestingly, the 3 cases
with t(11;14) displayed fewer or small-sized chromosomal alter-
ations; although the series is small, these findings are consistent with
those reported by Bryce et al4 using a reduced number of FISH probes.
CNN-LOHwere also detected in approximately half of the cases (5/11;
mean, 1.6 CNN-LOH/patient) (Figure 1C). Because of the lack of data
on the mutation landscape of AL, we then investigated whether AL
could potentially harbor a unifyingmutation as occurs inWaldenstro¨m
macroglobulinemia.22 Overall, 94 SNVs were detected in 93 genes
among 5 AL-sequenced patients (median, 15 SNVs/case). Although 2
different SNVs in the XKR8 gene were noted, no recurrent mutations
were identified (Table 1). In contrast to the recently reported similarities
betweenAL andMM in their inherited susceptibility,23 all but 1 (KRAS
c.35G.T) SNV identified herein have not been previously reported
as significantly frequent in MM (supplemental Excel File 2)24,25;
however, approximately two-thirds (62/93) of themutated genes in AL
are also mutated in MM.24,25 Further studies are warranted to confirm
these findings in larger series of patients.
In summary, in this study, based on the analysis of highly purified
clonal PCs from patients with AL, we showed that although they
display similar iPEP to that of MM, their GEP is remarkably similar to
that of normal PCs; such stable transcriptomes could not be explained
by a lower genetic instability. First-ever WES revealed potential lack
of a unifying gene mutation in AL, and therefore further studies are
warranted to better understand the pathogenesis and predisposition of
AL clonal PCs to produce amyloid light-chain fibrils.
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